<\/strong><\/span><\/h4>\n<\/strong><\/span><\/h4>\nProf. Dr. Daciana Elena Br\u0103ni\u0219teanu<\/strong><\/span>
Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i
Spitalul Clinic Universitar CF Ia\u0219i<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ locked=”off” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.17.1″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Simpozion NOVARTIS<\/span><\/p>\nCosentyx – It\u2019s all about the patient<\/span>
\u00a0\u2018\u2019Xolair- Game Changer \u00een Urticaria Cronic\u0103 Spontan\u0103\u2019\u2019
Prof. Daciana Br\u0103nisteanu – Clinica de Dermatologie, Spitalul Clinic CF Ia\u0219i
Prof. C\u0103lin Giurcaneanu – Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti;
Dr. Alin Nicolescu – Centrul Med. de Diagnostic si Tratament \u201cS.R.I.\u201d, Bucure\u0219ti<\/span><\/p>\nCuvinte cheie: omalizumab, urticarie cronic\u0103 spontan\u0103, papule, angioedem.<\/p>\n
<\/p>\n
Urticaria Cronic\u0103 Spontan\u0103 este o afec\u021biune cronic\u0103 intermitent\u0103, caracterizat\u0103 prin apari\u021bia spontan\u0103 a papulelor sau\/\u0219i a angioedemului, in fiecare zi sau aproape in toate zilele, pentru cel pu\u021bin 6 s\u0103pt\u0103m\u00e2ni, f\u0103r\u0103 un stimul extern evident.
Urticaria cronica spontana are un impact major asupra calitatii vietii si activitatilor zilnice ale pacientilor afectand multiple aspecte precum pierderea productivitatii, absenta de la locul de munca sau afectarea emotionala si psihologica.
Papulele \u0219i angioedemul sunt raportate in procente de 33 p\u00e2na la 67% la pacien\u021bii cu UCS, angioedemul singur fiind prezent doar la 1\u221213% din pacien\u021bi.
Terapia simptomatic\u0103 cu antihistaminice H1 este singura terapie de prim\u0103 inten\u021bie in UCS, dar \u00eensa efectul terapeutic este dovedit la mai pu\u021bin de 50 % dintre pacien\u021bii cu urticarie cronic\u0103 spontan\u0103, simptomele \u0219i RA ale tratamentului determin\u00e2nd pierderea energiei \u0219i afectarea somnului.<\/p>\n
Scopul tratamentului \u00een urticaria cronic\u0103 spontan\u0103 este obtinerea controlului complet al bolii cu absen\u0163a semnelor \u015fi simptomelor, precum \u015fi \u00eembunat\u0103\u021birea calit\u0103\u0163ii vie\u0163ii. Acest lucru poate fi m\u0103surat prin utilizarea \u00een practica clinic\u0103 a chestionarelor: UAS7- scorul de activitate al urticariei \u015fi DLQI- indicele dermatologic de calitate a vie\u0163ii, care ajuta in evaluarea rapid\u0103 a severit\u0103\u021bii UCS \u0219i in stabilirea algoritmului potrivit de tratament.<\/p>\n
Omalizumab este indicat ca tratament adjuvant al UCS la pacien\u0163i adul\u0163i \u015fi adolescen\u0163i (12 ani \u0219i peste) cu r\u0103spuns neadecvat la tratamentul cu antihistaminice H1.
Doza recomandat\u0103 este de 300 mg, subcutanat, la intervale de 4 s\u0103pt\u0103m\u00e2ni.<\/p>\n
\u00cen studiile de faz\u0103 III (Asteria I, Asteria II, Glacial) omalizumab administrat in doz\u0103 de 300 mg a demonstrat \u00een mod constant \u00eembunata\u021biri semnificative ale simptomelor UCS \u00een compara\u021bie cu placebo.
Terapia biologic\u0103, omalizumab a demonstrat c\u0103 ob\u021bine controlul rapid \u0219i complet al urticariei cronice spontane, av\u00e2nd un profil de siguran\u021b\u0103 dovedit atat de studiile clinice de faza III c\u00e2t si de eviden\u021bele real world.<\/p>\n
<\/span><\/p>\nSimpozion NOVARTIS<\/span><\/p>\nCosentyx – It\u2019s all about the patient<\/span>
\u00a0Moderator
Prof Univ Dr Daciana Elena Br\u0103ni\u0219teanu
Lectori
Prof Univ Dr Codrina Ancu\u021ba
Dr Georgiana Mih\u0103il\u0103<\/span><\/p>\nBoala psoriazic\u0103 este o afec\u021biune sistemic\u0103 inflamatorie, mediat\u0103 imun, progresiv\u0103, care afecteaz\u0103 \u00eentreg organismul, trec\u00e2nd dincolo de piele. Pentru pacien\u021bii cu boal\u0103 psoriazic\u0103, pielea este doar unul dintre aspectele bolii.<\/p>\n
Pacien\u021bii \u00ee\u0219i doresc un tratament cu eficien\u021b\u0103 dovedit\u0103 \u0219i profil favorabil de siguran\u021b\u0103, care s\u0103 \u021binteasc\u0103 toate manifest\u0103rile bolii psoriazice:
-Vindecarea leziunilor cutanate
-Remisiunea sus\u021binut\u0103 a artritei psoriazice
-Tratamentul complet al tuturor manifestarilor bolii, inclusiv al formelor \u201edificil de tratat\u201d
-Controlul comorbidit\u0103\u021bilor prezente \u0219i prevenirea aparitiei altor comorbidit\u0103\u021bi
-\u00cembun\u0103t\u0103\u021birea calit\u0103\u021bii vie\u021bii , at\u00e2t fizic c\u00e2t \u0219i psihic
\u00cendeplinirea acestor deziderate presupune diagnosticul, \u0219i implicit, tratamentul precoce al bolii.<\/p>\n
Date din literatura de specialitate relev\u0103 c\u0103, \u00een medie, exist\u0103 o \u00eent\u00e2rziere a diagnosticului de psoriazis de aproximativ 2,6 ani de la debutul bolii, \u00een timp ce pentru diagnosticul de artrit\u0103 psoriazic\u0103 aceast\u0103 \u00eent\u00e2rziere este \u00een medie de 1,8 ani de la debutul simptomelor.<\/p>\n
Cu at\u00e2t mai important\u0103 devine cunoa\u0219terea de c\u0103tre pacient a semnelor \u0219i simptomelor bolii psoriazice \u00eenc\u0103 din stadiul ini\u021bial.<\/p>\n
Un studiu recent derulat a scos \u00een eviden\u021b\u0103 faptul c\u0103 numero\u0219i pacien\u021bi cu boal\u0103 psoriazic\u0103 nu realizeaz\u0103 complexitatea acestei afec\u021biuni \u0219i nici rela\u021bia \u00eentre diferitele manifest\u0103ri ale bolii \u0219i comorbidit\u0103\u021bile asociate.<\/p>\n
Din acela\u0219i studiu reiese c\u0103, \u00een ceea ce prive\u0219te calitatea vie\u021bii, 73% dintre pacien\u021bi raporteaz\u0103 un impact moderat p\u00e2n\u0103 la foarte mare sau extrem de mare al bolii psoriazice.<\/p>\n
Tratamentul eficient \u0219i complet al manifest\u0103rilor multiple ale bolii psoriazice este esen\u021bial pentru \u00eembun\u0103t\u0103\u021birea calit\u0103\u021bii vie\u021bii pacien\u021bilor.<\/p>\n
Utilizat la nivel mondial la peste 500.000 pacien\u021bi, \u00een indica\u021biile aprobate, \u0219i f\u0103r\u0103 eviden\u021bierea de noi semnale privind siguran\u021ba de-a lungul a 5 ani, Cosentyx asigur\u0103 tratamentul complet pentru boala psoriazic\u0103.<\/p>\n
\u00cencep\u00e2nd din timp tratamentul bolii psoriazice \u0219i \u021bintind direct cauza bolii, inflama\u021bia sistemic\u0103, cu Cosentyx, ob\u021binem \u00een timp scurt o eficacitate \u00eenalt\u0103 care este sus\u021binut\u0103 pe termen lung, nu doar la nivelul pieli, dar \u0219i la nivel articular, \u00een condi\u021biile unui profil de siguran\u021b\u0103 favorabil \u0219i men\u021binut \u00een timp.<\/p>\n
<\/span><\/p>\n<\/span><\/p>\nSimpozion NDMEDHEALTH \/ URIAGE<\/span><\/p>\nINOVA\u021aIA URIAGE BARI\u00c9SUN 100: ULTRA PROTEC\u021aIE PENTRU PREVENIREA DETERIOR\u0102RII CELULARE \u0218I FOTO\u00ceMB\u0102TR\u00c2NIRII INDUSE DE RAZELE UV \u0218I LUMINA ALBASTR\u0102<\/span>
\u00a0Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i. Spitalul Clinic Universitar CF Ia\u0219i<\/p>\n
Cuvinte cheie: fotoprotec\u021bie, lumina albastr\u0103, piele intolerant\u0103, protec\u021bie a ADN-ului celular<\/p>\n
Tenul deschis si foarte deschis, pacien\u021bii cu piele intolerant\u0103, keratoze \u0219i fotodermatoze actinice sau cu diverse patologii care pot fi agravate de soare precum cuperoza, vitiligo, herpes, melasma au nevoie de produse speciale de protec\u021bie solar\u0103.
Aici intervine conceptul BARI\u00c9SUN 100, un produs ULTRA FOTOPROTECTOR ideal pentru to\u021bi pacien\u021bii cu fototipuri deschise \u0219i foarte deschise, cu intoleran\u021b\u0103 la soare \u0219i fotodermatoze, dermatoze agravate sau risc de sensibilizare la soare prin diferite tratamente.
Bari\u00e9sun 100 garanteaz\u0103 ultra-protec\u021bie pe trei direc\u021bii. \u00cen primul r\u00e2nd, datorit\u0103 ac\u021biunii brevetului Bari\u00e9sun, care limiteaz\u0103 pierderea de ap\u0103 transepidermic\u0103. Complexul de filtre organice UV ofer\u0103 protec\u021bie anti-UVA \u0219i anti-UVB (raze scurte \u0219i lungi) \u00een timp ce complexul patentat PVP + polyquaternium limiteaz\u0103 penetrarea \u00een epiderm\u0103 a filtrelor optimiz\u00e2nd astfel fotoprotec\u021bia.
Aceast\u0103 tripl\u0103 protec\u021bie include \u0219i propriet\u0103\u021bile antioxidante \u0219i de protec\u021bie a ADN-ului a apei termale Uriage combinate cu vitaminele C \u0219i E, care limiteaz\u0103 formarea de radicali liberi genera\u021bi de expunerea la soare.
\u00cen cele din urm\u0103, inova\u021bia major\u0103 a acestei game, brevetul Telomeres Protect previne deteriorarea celular\u0103 \u0219i foto\u00eemb\u0103tr\u00e2nirea datorit\u0103 unui extract patentat de arthrospira platensis (spirulin\u0103) care limiteaz\u0103 formarea telomerilor scur\u021bi prin calea mTOR, iar aquasponginele ofer\u0103 protec\u021bie anti-deshidratare.
Brevetul Telomeres Protect va reduce daunele celulare \u0219i va preveni foto\u00eemb\u0103tr\u00e2nirea prin trei ac\u021biuni. O reducere a activ\u0103rii complexului mTOR1, implicat \u00een mecanismele carcinogenezei, o reducere a produc\u021biei de progerin\u0103, o protein\u0103 toxic\u0103 produs\u0103 \u00een timpul \u00eemb\u0103tr\u00e2nirii \u0219i, \u00een final, o reducere a procentului de telomeri scur\u021bi.<\/p>\n
URIAGE BARI\u00c9SUN 100 INNOVATION: ULTRA PROTECTION TO PREVENT CELL DAMAGE AND PHOTO-AGING FROM UV AND BLUE LIGHT<\/span>
\u00a0Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, Ia\u0219i. CF Ia\u0219i University Clinical Hospital<\/p>\n
Keywords: photo protection, blue light, intolerant skin, cellular DNA protection<\/p>\n
Fair and very fair skin, patients with actinic keratoses and photo-dermatoses or with pathologies and intolerant skin that can be aggravated by the sun such as couperose, vitiligo, herpes, melasma need special sun protection products.
Hence the launch of BARIESUN 100, an ULTRA PHOTOPROTECTIVE product ideal for all your patients with light and very light phototypes, intolerant to the sun and all cases of photodermatoses, aggravated dermatoses or risk of sensitization to the sun by the various treatments.
Bari\u00e9sun 100 guarantees ultra-protection, triple protection. First of all, thanks to the action of the Bari\u00e9sun patent, which limits the transepidermal water loss. The complex of organic UV filters provides long and short anti-UVA and anti-UVB protection while the patented PVP + polyquaternium association limits the epidermal penetration of the filters thus optimizing photoprotection.
This triple protection also includes the antioxidant and DNA-protecting properties of Uriage Thermal Water combined with vitamins C and E, which limit the formation of free radicals generated by sun exposure.
Finally, the major innovation of this range, the Telomeres Protect patent, which prevents cellular damages and photoaging thanks to a patented extract of arthrospira platensis (spirulina) that limits the formation of short telomeres via the mTOR pathway. Not to mention the aquaspongins providing anti-dehydration protection.
The Telomeres Protect patent will reduce cellular damage and prevent photoaging through three actions. A reduction in the activation of the mTOR1 complex, involved in the mechanisms of carcinogenesis, a reduction in the production of progerin, a toxic protein produced during aging and finally a reduction in the percentage of short telomeres.<\/p>\n
Simpozion NDMEDHEALTH \/ ISDIN<\/span><\/p>\nALGORITMUL TERAPEUTIC \u00ceN KERATOZA ACTINIC\u0102 \u0218I ROLUL FOTOPROTEC\u021aIEI ISDIN \u00ceN PREVEN\u021aIA CANCERULUI DE PIELE NON-MELANOM<\/span>
\u00a0Daciana Br\u0103ni\u0219teanu<\/span><\/p>\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i. Spitalul Clinic Universitar CF Ia\u0219i<\/p>\n
Cuvinte cheie: keratoz\u0103 actinic\u0103, cancer de piele non-melanon, fotoliaz\u0103 \u00eencapsulat\u0103 \u00een lipozomi<\/p>\n
Keratoza actinic\u0103 (KA) este o form\u0103 frecvent \u00eent\u00e2lnit\u0103 de leziune pre-canceroas\u0103 a pielii, cauzat\u0103 de expunerea cronic\u0103 la radia\u021biile UV, a c\u0103ror principal\u0103 surs\u0103 este soarele.
Abordarea terapeutic\u0103 a KA depinde de \u00eencadrarea pacientului \u00een func\u021bie de recomand\u0103rile stabilite de Liga Interna\u021bional\u0103 a Societ\u0103\u021bilor Dermatologice (ILDS) \u0219i trebuie s\u0103 \u021bin\u0103 cont de: num\u0103rul, modul de distribuire \u0219i caracteristicile leziunilor, de preferin\u021ba pacientului privind modul de tratament (acas\u0103 sau la cabinet), durata terapiei, toleran\u021ba la efectele secundare (de exemplu, durere, inflama\u021bie, hipo-pigmentare, cicatrici), disponibilitate \u0219i cost.
Terapia fotodinamic\u0103 (TFD) \u0219i Crioterapia reprezint\u0103 abord\u0103ri terapeutice consacrate \u00een tratamentul KA.
Totu\u0219i, dup\u0103 acestea, strategiile de protec\u021bie solar\u0103 sunt importante pentru a reduce riscul form\u0103rii de noi leziuni \u0219i\/sau nevoia de a folosi din nou TFD \u0219i Crioterapie.
Studii recente, majoritatea efectuate \u00een Europa, dovedesc valoarea clinic\u0103 a produselor de protec\u021bie solar\u0103 care con\u021bin enzime de fotoliaz\u0103 \u00eencapsulate \u00een lipozomi \u00een cazul pacien\u021bilor care urmeaz\u0103 un tratament pentru KA, al pacien\u021bilor cu grad de risc Fitzpatrick foarte ridicat (I-III) \u0219i al celor care necesit\u0103 suport suplimentar \u00een chemo-preven\u021bie \u00een cazul bolilor cronice sau tratamentelor medicale.
Fotoliaza repar\u0103 muta\u021biile \u0219i leziunile de ADN induse de radia\u021biile UV, influen\u021b\u00e2nd astfel etapele ini\u021biale de carcinogenez\u0103.
Strategia de fotoprotec\u021bie+fotoreparare trebuie inclus\u0103 \u00een algoritmul terapeutic de preven\u021bie \u0219i tratament \u00een KA \u0219i cancer de piele non-melanom. Folosirea ISDIN Eryfotona, cu tehnologie inovatoare DNA Repairsomes \u0219i fotoliaz\u0103 \u00eencapsulat\u0103 \u00een lipozomi a demonstrat rezultate ca monoterapie pentru pacien\u021bii cu form\u0103 u\u0219oar\u0103 de KA, precum \u0219i ca adjuvant \u00een TFD \u0219i crioterapie.<\/p>\n
THERAPEUTIC ALGORITHM IN ACTINIC KERATOSIS AND THE ROLE OF ISDIN PHOTOPROTECTION IN THE PREVENTION OF NON MELANOMA SKIN CANCER<\/span>
\u00a0Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i. Spitalul Clinic Universitar CF Ia\u0219i<\/p>\n
Key words: actinic keratosis, non melanona skin cancer, photolyase encapsulated in liposomes<\/p>\n
Actinic Keratosis (AK) is a frequent form of pre-cancerous skin lesion, caused by cronic exposure to UV radiation, with the sun as the main source.
The therapeutic approach in AK depends on the patients\u2019 classification based on the recommendations of the International Leage of Dermatological Societies (ILDS) and must consider: the number, distribution and characteristics of the lesions, patient\u2019s preffered way of treatment (at home or in doctor\u2019s office), duration of the therapy, tolerance to side effects (e.g. pain, inflamation, hypo-pigmentation, scarring), availability and cost.
Photodynamic Therapy (PDT) and Cryotherapy represent standard therapeutic approaches in the treatment of AK.
However, after them, sun protection strategies are important for reducing the risc of new lesions and\/or the need to use PDT and Cryotherapy again.
Recent studies, most of them performed in Europe, confirm the clinical value of photoprotection products containing photolyase enzimes encapsulated in liposomes in pacients that follow a treatment for KA, those with very high Fitzpatrick risk (I-III) and those who need additional care in chemo-prevention in cronical illnesses or medical treatments.
The photolyase repairs the DNA mutations and lesions caused by the UV radiation, thus influencing the initial stages of carcinogenesis.
A photoprotection and photorepair strategy must be included in the therapeutic algorithm of prevention and treatment of AK and NMSC. ISDIN Eryfotona, with innovative technology of DNA Repairsomes and photolyase encapsulated in lipozomes, has proven results when used as monotherapy in patients with less severe forms of AK, as well as co-adjuvant in PDT and Cryotherapy.<\/p>\n
Simpozion Lilly<\/span><\/p>\nTALTZ \u00ceN PSORIAZIS: EFICACITATE SUPERIOAR\u0102 DIN CAP P\u00c2N\u0102-N PICIOARE<\/span>
Lectori: Daciana Br\u0103ni\u0219teanu1, Cristina Tutunaru2, Andreea Molodoi3, Elena Porumb-Andrese1<\/span><\/p>\n1Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, 2Universitatea de Medicin\u0103 \u0219i Farmacie Craiova, 3Spitalul Municipal Roman<\/p>\n
Cuvinte cheie: Psoriazis, Taltz, Ixekizumab, IL-17, piele complet curat\u0103.
De-a lungul celor aproape 30 de ani de activitate \u00een Rom\u00e2nia, Lilly a pus la dispozi\u021bia medicilor \u0219i pacien\u021bilor peste 30 de medicamente inovatoare \u00een domenii precum diabetul zaharat, oncologia, dermatologia, endocrinologia, reumatologia, neurologia, urologia. Anual, peste 100.000 de pacien\u021bi rom\u00e2ni beneficiaz\u0103 de terapiile moderne ale companiei Lilly.
Misiunea noastr\u0103 \u00een imunologie este aceea de a \u00eembun\u0103t\u0103\u021bi via\u021ba pacien\u021bilor \u0219i consider\u0103m c\u0103 medicamentele noastre pot redefini op\u021biunile terapeutice \u00een psoriazis, dermatita atopic\u0103, artrita psoriazic\u0103, artrita reumatoid\u0103, spondiloartritele axiale, bolile inflamatorii intestinale, acest lucru \u00eensemn\u00e2nd ridicarea continu\u0103 a \u0219tachetei \u00een acest domeniu.
\u021ain\u00e2nd cont de natura inflamatorie cronic\u0103 a psoriazisului \u0219i de multiplele comorbidit\u0103\u021bi asociate, este nevoie de o gestionare pe termen lung a acestei afec\u021biuni, de cele mai multe ori pe toat\u0103 durata vie\u021bii.
Taltz, anticorp monoclonal cu afinitate ridicat\u0103 \u0219i specificitate pentru interleukina 17A, \u0219i-a demonstrat eficacitatea \u0219i siguran\u021ba la 5 ani de tratament, dovedind c\u0103 este un tratament complet pentru pacien\u021bii cu psoriazis care \u00ee\u0219i doresc un r\u0103spuns rapid \u0219i men\u021binut pe termen lung. Totodat\u0103, av\u00e2nd un profil de siguran\u021b\u0103 bine definit, Taltz a atins \u00een studiile clinice niveluri superioare de r\u0103spuns inclusiv la nivel palmo-plantar, unghial, genital \u0219i la nivelulul scalpului, fiind eficient nu numai la nivel cutanat ci \u0219i la nivel articular.<\/p>\n
TALTZ IN PSORIASIS: SUPERIOR EFFICACY FROM HEAD TO TOE<\/span>
Speakers: Daciana Br\u0103ni\u0219teanu1, Cristina Tutunaru2, Andreea Molodoi3, Elena Porumb-Andrese1<\/span><\/p>\n1MF Grigore T. Popa, Ia\u0219i, 2UMF Craiova, 3Spitalul Municipal Roman<\/p>\n
Keywords: emollients, newborns, infants, side effects, benefits<\/p>\n
Keywords: psoriasis, Taltz, Ixekizumab, IL-17, completely clear skin.
During its almost 30 years of activity in Romania, Lilly has made over 30 innovative medicines available to physicians and patients from therapeutic areas such as diabetes, oncology, dermatology, endocrinology, rheumatology, neurology, urology. Every year, over 100,000 Romanian patients benefit from Lilly’s modern therapies.
Our mission in immunology is to improve the lives of patients and we believe that our drugs can redefine the therapeutic options in psoriasis, atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, axial spondylarthritis, inflammatory bowel disease, which means continuously raising the bar.
Given the chronic inflammatory nature of psoriasis and the multiple associated comorbidities, long-term management of this condition, most often throughout life, is required.
Taltz, a monoclonal antibody with high affinity and specificity for IL-17A, demonstrated efficacy and safety at 5 years, proving that it is a complete treatment for psoriasis patients who want a fast and long-term response. At the same time, with a well-defined safety profile, Taltz has achieved higher levels of response in clinical trials, including at the palm-plantar, nail, genital, and scalp levels, being effective not only on the skin but also on the joints.<\/p>\n
Scurt CV<\/span><\/p>\n\u2013 Profesor universitar, titular de curs de dermatologie, Facultatea de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i
\u2013 Doctor \u00een \u0219tiin\u021be medicale, teza de doctorat \u00een ACNEEA VULGARA (2004)
\u2013 Manager al Centrului de Dermatologie, Venerologie \u0219i Dermatocosmetologie \u201cDermaLux\u201d, din 2004 p\u00e2n\u0103 \u00een prezent
\u2013 \u0218ef sec\u021bie la Clinica Dermatologic\u0103 a Spitalului Clinic C\u0103i Ferate Ia\u0219i
\u2013 Competen\u021be \u00een anatomie patologic\u0103 cutanat\u0103 (Lyon, Fran\u021ba) \u0219i \u00een dermatocosmetologie
\u2013 Cursuri de supraspecializare \u00een Fran\u021ba, Lyon, Universite Lyon 2 (AFSA), cursuri europene de dermatoscopie, boala venoas\u0103 cronic\u0103, psoriazis, anti-aging, injectare de filere, laserterapie etc.
\u2013 Preocup\u0103ri deosebite pentru psoriazis: coordonator al Proiectului Na\u021bional Educa\u021bional \u201cPatologia psoriazisului\u201d, particip\u0103ri \u00een calitate de expert la \u00eent\u00e2lniri interna\u021bionale pe teme de psoriasis (Viena, Atena, Geneva etc.), articole publicate \u00een reviste na\u021bionale \u0219i interna\u021bionale, comunic\u0103ri orale, conferin\u021be, grupuri de lucru \u0219i workshop-uri pe tema psoriazisului
\u2013 Pre\u0219edinte al Asocia\u021biei Dermatologilor din Moldova, Pre\u0219edinte al manifest\u0103rii na\u021bionale cu participare interna\u021bional\u0103 \u201cPrim\u0103vara Dermatologic\u0103 Ie\u0219ean\u0103\u201d;
\u2013 Membru \u00een Comitetul Director al Societ\u0103\u021bii Rom\u00e2ne de Dermatologie
\u2013 Membru \u00een Grupul Interna\u021bional \u201cMedical Reporter\u2019s Academy\u201d, pe probleme de flebologie
\u2013 Membru al: Academiei Europene de Dermatologie, Academiei Americane de Dermatologie, Societ\u0103\u021bii Franceze de Dermatologie, Societ\u0103\u021bii Franceze de Flebologie, Societ\u0103\u021bii Interna\u021bionale de Dermatologie, Societ\u0103\u021bii de Dermatologie Investigativ\u0103, Societ\u0103\u021bii Rom\u00e2ne de Dermatopediatrie, Societ\u0103\u021bii Rom\u00e2ne de Dermatoimunologie, Societ\u0103\u021bii de Medici \u0219i Naturali\u0219ti
\u2013 Coordonator a peste 100 de cursuri de educa\u021bie medical\u0103 continu\u0103 \u0219i de cursuri postuniversitare
\u2013 Peste 400 de conferin\u021be, prelegeri \u0219i comunic\u0103ri orale sus\u021binute la manifest\u0103ri \u0219tiin\u021bifice, mese rotunde, conferin\u021be \u0219i congrese din \u021bar\u0103, nu doar de dermatologie
\u2013 Lector invitat la Congrese Interna\u021bionale ale: Societ\u0103\u021bii Europene de Dermatologie \u0219i Venerologie (EADV), Societ\u0103\u021bii Franceze de Flebologie (SFP), Uniunii Interna\u021bionale de Flebologie (UIP)
\u2013 Expert \u00een Boala Venoas\u0103 Cronic\u0103, \u00een Maladii Transmisibile Sexual, expert dermatolog \u00een solu\u021bionarea unor cazuri medico-legale
\u2013 Decan de Serie desemnat de c\u0103tre studen\u021bi, ca semn de respect \u0219i de recunoa\u0219tere a calit\u0103\u021bii de dasc\u0103l
\u2013 Implicare activ\u0103 \u00een activitatea de cercetare \u0219tiin\u021bific\u0103 (granturi de cercetare \u0219tiin\u021bific\u0103, proiecte na\u021bionale \u0219i interna\u021bionale, studii clinice, consultant \u0219tiin\u021bific, membru \u00een numeroase advisory board-uri etc.)
\u2013 Peste 230 de lucr\u0103ri publicate \u00een \u021bar\u0103 \u0219i \u00een str\u0103in\u0103tate, autoare a 23 c\u0103r\u021bi \u0219i capitole de c\u0103r\u021bi de dermatologie
\u2013 Absolvent\u0103 a Facult\u0103\u021bii de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i, promo\u021bia 1991<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2022\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”4.16″ custom_padding=”61px|0px|69px|0px|false|false” global_colors_info=”{}”][et_pb_column type=”3_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2022<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.16″ _unique_id=”794aaef5-e005-432a-99fb-9ca53e06d67b” title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A” global_colors_info=”{}”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” global_colors_info=”{}”]<\/p>\n
Operatorul PDI 2022<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.16″ text_font=”||||||||” global_colors_info=”{}”]<\/p>\n
![\"\"](\"https:\/\/pdi.ro\/2022\/wp-content\/uploads\/2020\/02\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: contact@pdi.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”on|on|on” _builder_version=”4.16″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” disabled=”on” locked=”off” global_colors_info=”{}”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”9252,9464,10556″ fullwidth=”on” disabled_on=”off|off|off” _builder_version=”4.17.1″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off” global_colors_info=”{}”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Prof. Dr. Daciana Elena Br\u0103ni\u0219teanuUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219iSpitalul Clinic Universitar CF Ia\u0219iSimpozion NOVARTIS Cosentyx – It\u2019s all about the patient\u00a0\u2018\u2019Xolair- Game Changer \u00een Urticaria Cronic\u0103 Spontan\u0103\u2019\u2019Prof. Daciana Br\u0103nisteanu – Clinica de Dermatologie, Spitalul Clinic CF Ia\u0219iProf. C\u0103lin Giurcaneanu – Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti;Dr. Alin Nicolescu – Centrul Med. […]<\/p>\n","protected":false},"author":2,"featured_media":11595,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[12],"tags":[],"class_list":["post-11586","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lectori"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts\/11586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/comments?post=11586"}],"version-history":[{"count":11,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts\/11586\/revisions"}],"predecessor-version":[{"id":11638,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts\/11586\/revisions\/11638"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/media\/11595"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/media?parent=11586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/categories?post=11586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/tags?post=11586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Prof. Dr. Daciana Elena Br\u0103ni\u0219teanu<\/strong><\/span>
Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i
Spitalul Clinic Universitar CF Ia\u0219i<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ locked=”off” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.17.1″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Simpozion NOVARTIS<\/span><\/p>\nCosentyx – It\u2019s all about the patient<\/span>
\u00a0\u2018\u2019Xolair- Game Changer \u00een Urticaria Cronic\u0103 Spontan\u0103\u2019\u2019
Prof. Daciana Br\u0103nisteanu – Clinica de Dermatologie, Spitalul Clinic CF Ia\u0219i
Prof. C\u0103lin Giurcaneanu – Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti;
Dr. Alin Nicolescu – Centrul Med. de Diagnostic si Tratament \u201cS.R.I.\u201d, Bucure\u0219ti<\/span><\/p>\nCuvinte cheie: omalizumab, urticarie cronic\u0103 spontan\u0103, papule, angioedem.<\/p>\n
<\/p>\n
Urticaria Cronic\u0103 Spontan\u0103 este o afec\u021biune cronic\u0103 intermitent\u0103, caracterizat\u0103 prin apari\u021bia spontan\u0103 a papulelor sau\/\u0219i a angioedemului, in fiecare zi sau aproape in toate zilele, pentru cel pu\u021bin 6 s\u0103pt\u0103m\u00e2ni, f\u0103r\u0103 un stimul extern evident.
Urticaria cronica spontana are un impact major asupra calitatii vietii si activitatilor zilnice ale pacientilor afectand multiple aspecte precum pierderea productivitatii, absenta de la locul de munca sau afectarea emotionala si psihologica.
Papulele \u0219i angioedemul sunt raportate in procente de 33 p\u00e2na la 67% la pacien\u021bii cu UCS, angioedemul singur fiind prezent doar la 1\u221213% din pacien\u021bi.
Terapia simptomatic\u0103 cu antihistaminice H1 este singura terapie de prim\u0103 inten\u021bie in UCS, dar \u00eensa efectul terapeutic este dovedit la mai pu\u021bin de 50 % dintre pacien\u021bii cu urticarie cronic\u0103 spontan\u0103, simptomele \u0219i RA ale tratamentului determin\u00e2nd pierderea energiei \u0219i afectarea somnului.<\/p>\n
Scopul tratamentului \u00een urticaria cronic\u0103 spontan\u0103 este obtinerea controlului complet al bolii cu absen\u0163a semnelor \u015fi simptomelor, precum \u015fi \u00eembunat\u0103\u021birea calit\u0103\u0163ii vie\u0163ii. Acest lucru poate fi m\u0103surat prin utilizarea \u00een practica clinic\u0103 a chestionarelor: UAS7- scorul de activitate al urticariei \u015fi DLQI- indicele dermatologic de calitate a vie\u0163ii, care ajuta in evaluarea rapid\u0103 a severit\u0103\u021bii UCS \u0219i in stabilirea algoritmului potrivit de tratament.<\/p>\n
Omalizumab este indicat ca tratament adjuvant al UCS la pacien\u0163i adul\u0163i \u015fi adolescen\u0163i (12 ani \u0219i peste) cu r\u0103spuns neadecvat la tratamentul cu antihistaminice H1.
Doza recomandat\u0103 este de 300 mg, subcutanat, la intervale de 4 s\u0103pt\u0103m\u00e2ni.<\/p>\n
\u00cen studiile de faz\u0103 III (Asteria I, Asteria II, Glacial) omalizumab administrat in doz\u0103 de 300 mg a demonstrat \u00een mod constant \u00eembunata\u021biri semnificative ale simptomelor UCS \u00een compara\u021bie cu placebo.
Terapia biologic\u0103, omalizumab a demonstrat c\u0103 ob\u021bine controlul rapid \u0219i complet al urticariei cronice spontane, av\u00e2nd un profil de siguran\u021b\u0103 dovedit atat de studiile clinice de faza III c\u00e2t si de eviden\u021bele real world.<\/p>\n
<\/span><\/p>\nSimpozion NOVARTIS<\/span><\/p>\nCosentyx – It\u2019s all about the patient<\/span>
\u00a0Moderator
Prof Univ Dr Daciana Elena Br\u0103ni\u0219teanu
Lectori
Prof Univ Dr Codrina Ancu\u021ba
Dr Georgiana Mih\u0103il\u0103<\/span><\/p>\nBoala psoriazic\u0103 este o afec\u021biune sistemic\u0103 inflamatorie, mediat\u0103 imun, progresiv\u0103, care afecteaz\u0103 \u00eentreg organismul, trec\u00e2nd dincolo de piele. Pentru pacien\u021bii cu boal\u0103 psoriazic\u0103, pielea este doar unul dintre aspectele bolii.<\/p>\n
Pacien\u021bii \u00ee\u0219i doresc un tratament cu eficien\u021b\u0103 dovedit\u0103 \u0219i profil favorabil de siguran\u021b\u0103, care s\u0103 \u021binteasc\u0103 toate manifest\u0103rile bolii psoriazice:
-Vindecarea leziunilor cutanate
-Remisiunea sus\u021binut\u0103 a artritei psoriazice
-Tratamentul complet al tuturor manifestarilor bolii, inclusiv al formelor \u201edificil de tratat\u201d
-Controlul comorbidit\u0103\u021bilor prezente \u0219i prevenirea aparitiei altor comorbidit\u0103\u021bi
-\u00cembun\u0103t\u0103\u021birea calit\u0103\u021bii vie\u021bii , at\u00e2t fizic c\u00e2t \u0219i psihic
\u00cendeplinirea acestor deziderate presupune diagnosticul, \u0219i implicit, tratamentul precoce al bolii.<\/p>\n
Date din literatura de specialitate relev\u0103 c\u0103, \u00een medie, exist\u0103 o \u00eent\u00e2rziere a diagnosticului de psoriazis de aproximativ 2,6 ani de la debutul bolii, \u00een timp ce pentru diagnosticul de artrit\u0103 psoriazic\u0103 aceast\u0103 \u00eent\u00e2rziere este \u00een medie de 1,8 ani de la debutul simptomelor.<\/p>\n
Cu at\u00e2t mai important\u0103 devine cunoa\u0219terea de c\u0103tre pacient a semnelor \u0219i simptomelor bolii psoriazice \u00eenc\u0103 din stadiul ini\u021bial.<\/p>\n
Un studiu recent derulat a scos \u00een eviden\u021b\u0103 faptul c\u0103 numero\u0219i pacien\u021bi cu boal\u0103 psoriazic\u0103 nu realizeaz\u0103 complexitatea acestei afec\u021biuni \u0219i nici rela\u021bia \u00eentre diferitele manifest\u0103ri ale bolii \u0219i comorbidit\u0103\u021bile asociate.<\/p>\n
Din acela\u0219i studiu reiese c\u0103, \u00een ceea ce prive\u0219te calitatea vie\u021bii, 73% dintre pacien\u021bi raporteaz\u0103 un impact moderat p\u00e2n\u0103 la foarte mare sau extrem de mare al bolii psoriazice.<\/p>\n
Tratamentul eficient \u0219i complet al manifest\u0103rilor multiple ale bolii psoriazice este esen\u021bial pentru \u00eembun\u0103t\u0103\u021birea calit\u0103\u021bii vie\u021bii pacien\u021bilor.<\/p>\n
Utilizat la nivel mondial la peste 500.000 pacien\u021bi, \u00een indica\u021biile aprobate, \u0219i f\u0103r\u0103 eviden\u021bierea de noi semnale privind siguran\u021ba de-a lungul a 5 ani, Cosentyx asigur\u0103 tratamentul complet pentru boala psoriazic\u0103.<\/p>\n
\u00cencep\u00e2nd din timp tratamentul bolii psoriazice \u0219i \u021bintind direct cauza bolii, inflama\u021bia sistemic\u0103, cu Cosentyx, ob\u021binem \u00een timp scurt o eficacitate \u00eenalt\u0103 care este sus\u021binut\u0103 pe termen lung, nu doar la nivelul pieli, dar \u0219i la nivel articular, \u00een condi\u021biile unui profil de siguran\u021b\u0103 favorabil \u0219i men\u021binut \u00een timp.<\/p>\n
<\/span><\/p>\n<\/span><\/p>\nSimpozion NDMEDHEALTH \/ URIAGE<\/span><\/p>\nINOVA\u021aIA URIAGE BARI\u00c9SUN 100: ULTRA PROTEC\u021aIE PENTRU PREVENIREA DETERIOR\u0102RII CELULARE \u0218I FOTO\u00ceMB\u0102TR\u00c2NIRII INDUSE DE RAZELE UV \u0218I LUMINA ALBASTR\u0102<\/span>
\u00a0Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i. Spitalul Clinic Universitar CF Ia\u0219i<\/p>\n
Cuvinte cheie: fotoprotec\u021bie, lumina albastr\u0103, piele intolerant\u0103, protec\u021bie a ADN-ului celular<\/p>\n
Tenul deschis si foarte deschis, pacien\u021bii cu piele intolerant\u0103, keratoze \u0219i fotodermatoze actinice sau cu diverse patologii care pot fi agravate de soare precum cuperoza, vitiligo, herpes, melasma au nevoie de produse speciale de protec\u021bie solar\u0103.
Aici intervine conceptul BARI\u00c9SUN 100, un produs ULTRA FOTOPROTECTOR ideal pentru to\u021bi pacien\u021bii cu fototipuri deschise \u0219i foarte deschise, cu intoleran\u021b\u0103 la soare \u0219i fotodermatoze, dermatoze agravate sau risc de sensibilizare la soare prin diferite tratamente.
Bari\u00e9sun 100 garanteaz\u0103 ultra-protec\u021bie pe trei direc\u021bii. \u00cen primul r\u00e2nd, datorit\u0103 ac\u021biunii brevetului Bari\u00e9sun, care limiteaz\u0103 pierderea de ap\u0103 transepidermic\u0103. Complexul de filtre organice UV ofer\u0103 protec\u021bie anti-UVA \u0219i anti-UVB (raze scurte \u0219i lungi) \u00een timp ce complexul patentat PVP + polyquaternium limiteaz\u0103 penetrarea \u00een epiderm\u0103 a filtrelor optimiz\u00e2nd astfel fotoprotec\u021bia.
Aceast\u0103 tripl\u0103 protec\u021bie include \u0219i propriet\u0103\u021bile antioxidante \u0219i de protec\u021bie a ADN-ului a apei termale Uriage combinate cu vitaminele C \u0219i E, care limiteaz\u0103 formarea de radicali liberi genera\u021bi de expunerea la soare.
\u00cen cele din urm\u0103, inova\u021bia major\u0103 a acestei game, brevetul Telomeres Protect previne deteriorarea celular\u0103 \u0219i foto\u00eemb\u0103tr\u00e2nirea datorit\u0103 unui extract patentat de arthrospira platensis (spirulin\u0103) care limiteaz\u0103 formarea telomerilor scur\u021bi prin calea mTOR, iar aquasponginele ofer\u0103 protec\u021bie anti-deshidratare.
Brevetul Telomeres Protect va reduce daunele celulare \u0219i va preveni foto\u00eemb\u0103tr\u00e2nirea prin trei ac\u021biuni. O reducere a activ\u0103rii complexului mTOR1, implicat \u00een mecanismele carcinogenezei, o reducere a produc\u021biei de progerin\u0103, o protein\u0103 toxic\u0103 produs\u0103 \u00een timpul \u00eemb\u0103tr\u00e2nirii \u0219i, \u00een final, o reducere a procentului de telomeri scur\u021bi.<\/p>\n
URIAGE BARI\u00c9SUN 100 INNOVATION: ULTRA PROTECTION TO PREVENT CELL DAMAGE AND PHOTO-AGING FROM UV AND BLUE LIGHT<\/span>
\u00a0Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, Ia\u0219i. CF Ia\u0219i University Clinical Hospital<\/p>\n
Keywords: photo protection, blue light, intolerant skin, cellular DNA protection<\/p>\n
Fair and very fair skin, patients with actinic keratoses and photo-dermatoses or with pathologies and intolerant skin that can be aggravated by the sun such as couperose, vitiligo, herpes, melasma need special sun protection products.
Hence the launch of BARIESUN 100, an ULTRA PHOTOPROTECTIVE product ideal for all your patients with light and very light phototypes, intolerant to the sun and all cases of photodermatoses, aggravated dermatoses or risk of sensitization to the sun by the various treatments.
Bari\u00e9sun 100 guarantees ultra-protection, triple protection. First of all, thanks to the action of the Bari\u00e9sun patent, which limits the transepidermal water loss. The complex of organic UV filters provides long and short anti-UVA and anti-UVB protection while the patented PVP + polyquaternium association limits the epidermal penetration of the filters thus optimizing photoprotection.
This triple protection also includes the antioxidant and DNA-protecting properties of Uriage Thermal Water combined with vitamins C and E, which limit the formation of free radicals generated by sun exposure.
Finally, the major innovation of this range, the Telomeres Protect patent, which prevents cellular damages and photoaging thanks to a patented extract of arthrospira platensis (spirulina) that limits the formation of short telomeres via the mTOR pathway. Not to mention the aquaspongins providing anti-dehydration protection.
The Telomeres Protect patent will reduce cellular damage and prevent photoaging through three actions. A reduction in the activation of the mTOR1 complex, involved in the mechanisms of carcinogenesis, a reduction in the production of progerin, a toxic protein produced during aging and finally a reduction in the percentage of short telomeres.<\/p>\n
Simpozion NDMEDHEALTH \/ ISDIN<\/span><\/p>\nALGORITMUL TERAPEUTIC \u00ceN KERATOZA ACTINIC\u0102 \u0218I ROLUL FOTOPROTEC\u021aIEI ISDIN \u00ceN PREVEN\u021aIA CANCERULUI DE PIELE NON-MELANOM<\/span>
\u00a0Daciana Br\u0103ni\u0219teanu<\/span><\/p>\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i. Spitalul Clinic Universitar CF Ia\u0219i<\/p>\n
Cuvinte cheie: keratoz\u0103 actinic\u0103, cancer de piele non-melanon, fotoliaz\u0103 \u00eencapsulat\u0103 \u00een lipozomi<\/p>\n
Keratoza actinic\u0103 (KA) este o form\u0103 frecvent \u00eent\u00e2lnit\u0103 de leziune pre-canceroas\u0103 a pielii, cauzat\u0103 de expunerea cronic\u0103 la radia\u021biile UV, a c\u0103ror principal\u0103 surs\u0103 este soarele.
Abordarea terapeutic\u0103 a KA depinde de \u00eencadrarea pacientului \u00een func\u021bie de recomand\u0103rile stabilite de Liga Interna\u021bional\u0103 a Societ\u0103\u021bilor Dermatologice (ILDS) \u0219i trebuie s\u0103 \u021bin\u0103 cont de: num\u0103rul, modul de distribuire \u0219i caracteristicile leziunilor, de preferin\u021ba pacientului privind modul de tratament (acas\u0103 sau la cabinet), durata terapiei, toleran\u021ba la efectele secundare (de exemplu, durere, inflama\u021bie, hipo-pigmentare, cicatrici), disponibilitate \u0219i cost.
Terapia fotodinamic\u0103 (TFD) \u0219i Crioterapia reprezint\u0103 abord\u0103ri terapeutice consacrate \u00een tratamentul KA.
Totu\u0219i, dup\u0103 acestea, strategiile de protec\u021bie solar\u0103 sunt importante pentru a reduce riscul form\u0103rii de noi leziuni \u0219i\/sau nevoia de a folosi din nou TFD \u0219i Crioterapie.
Studii recente, majoritatea efectuate \u00een Europa, dovedesc valoarea clinic\u0103 a produselor de protec\u021bie solar\u0103 care con\u021bin enzime de fotoliaz\u0103 \u00eencapsulate \u00een lipozomi \u00een cazul pacien\u021bilor care urmeaz\u0103 un tratament pentru KA, al pacien\u021bilor cu grad de risc Fitzpatrick foarte ridicat (I-III) \u0219i al celor care necesit\u0103 suport suplimentar \u00een chemo-preven\u021bie \u00een cazul bolilor cronice sau tratamentelor medicale.
Fotoliaza repar\u0103 muta\u021biile \u0219i leziunile de ADN induse de radia\u021biile UV, influen\u021b\u00e2nd astfel etapele ini\u021biale de carcinogenez\u0103.
Strategia de fotoprotec\u021bie+fotoreparare trebuie inclus\u0103 \u00een algoritmul terapeutic de preven\u021bie \u0219i tratament \u00een KA \u0219i cancer de piele non-melanom. Folosirea ISDIN Eryfotona, cu tehnologie inovatoare DNA Repairsomes \u0219i fotoliaz\u0103 \u00eencapsulat\u0103 \u00een lipozomi a demonstrat rezultate ca monoterapie pentru pacien\u021bii cu form\u0103 u\u0219oar\u0103 de KA, precum \u0219i ca adjuvant \u00een TFD \u0219i crioterapie.<\/p>\n
THERAPEUTIC ALGORITHM IN ACTINIC KERATOSIS AND THE ROLE OF ISDIN PHOTOPROTECTION IN THE PREVENTION OF NON MELANOMA SKIN CANCER<\/span>
\u00a0Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i. Spitalul Clinic Universitar CF Ia\u0219i<\/p>\n
Key words: actinic keratosis, non melanona skin cancer, photolyase encapsulated in liposomes<\/p>\n
Actinic Keratosis (AK) is a frequent form of pre-cancerous skin lesion, caused by cronic exposure to UV radiation, with the sun as the main source.
The therapeutic approach in AK depends on the patients\u2019 classification based on the recommendations of the International Leage of Dermatological Societies (ILDS) and must consider: the number, distribution and characteristics of the lesions, patient\u2019s preffered way of treatment (at home or in doctor\u2019s office), duration of the therapy, tolerance to side effects (e.g. pain, inflamation, hypo-pigmentation, scarring), availability and cost.
Photodynamic Therapy (PDT) and Cryotherapy represent standard therapeutic approaches in the treatment of AK.
However, after them, sun protection strategies are important for reducing the risc of new lesions and\/or the need to use PDT and Cryotherapy again.
Recent studies, most of them performed in Europe, confirm the clinical value of photoprotection products containing photolyase enzimes encapsulated in liposomes in pacients that follow a treatment for KA, those with very high Fitzpatrick risk (I-III) and those who need additional care in chemo-prevention in cronical illnesses or medical treatments.
The photolyase repairs the DNA mutations and lesions caused by the UV radiation, thus influencing the initial stages of carcinogenesis.
A photoprotection and photorepair strategy must be included in the therapeutic algorithm of prevention and treatment of AK and NMSC. ISDIN Eryfotona, with innovative technology of DNA Repairsomes and photolyase encapsulated in lipozomes, has proven results when used as monotherapy in patients with less severe forms of AK, as well as co-adjuvant in PDT and Cryotherapy.<\/p>\n
Simpozion Lilly<\/span><\/p>\nTALTZ \u00ceN PSORIAZIS: EFICACITATE SUPERIOAR\u0102 DIN CAP P\u00c2N\u0102-N PICIOARE<\/span>
Lectori: Daciana Br\u0103ni\u0219teanu1, Cristina Tutunaru2, Andreea Molodoi3, Elena Porumb-Andrese1<\/span><\/p>\n1Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, 2Universitatea de Medicin\u0103 \u0219i Farmacie Craiova, 3Spitalul Municipal Roman<\/p>\n
Cuvinte cheie: Psoriazis, Taltz, Ixekizumab, IL-17, piele complet curat\u0103.
De-a lungul celor aproape 30 de ani de activitate \u00een Rom\u00e2nia, Lilly a pus la dispozi\u021bia medicilor \u0219i pacien\u021bilor peste 30 de medicamente inovatoare \u00een domenii precum diabetul zaharat, oncologia, dermatologia, endocrinologia, reumatologia, neurologia, urologia. Anual, peste 100.000 de pacien\u021bi rom\u00e2ni beneficiaz\u0103 de terapiile moderne ale companiei Lilly.
Misiunea noastr\u0103 \u00een imunologie este aceea de a \u00eembun\u0103t\u0103\u021bi via\u021ba pacien\u021bilor \u0219i consider\u0103m c\u0103 medicamentele noastre pot redefini op\u021biunile terapeutice \u00een psoriazis, dermatita atopic\u0103, artrita psoriazic\u0103, artrita reumatoid\u0103, spondiloartritele axiale, bolile inflamatorii intestinale, acest lucru \u00eensemn\u00e2nd ridicarea continu\u0103 a \u0219tachetei \u00een acest domeniu.
\u021ain\u00e2nd cont de natura inflamatorie cronic\u0103 a psoriazisului \u0219i de multiplele comorbidit\u0103\u021bi asociate, este nevoie de o gestionare pe termen lung a acestei afec\u021biuni, de cele mai multe ori pe toat\u0103 durata vie\u021bii.
Taltz, anticorp monoclonal cu afinitate ridicat\u0103 \u0219i specificitate pentru interleukina 17A, \u0219i-a demonstrat eficacitatea \u0219i siguran\u021ba la 5 ani de tratament, dovedind c\u0103 este un tratament complet pentru pacien\u021bii cu psoriazis care \u00ee\u0219i doresc un r\u0103spuns rapid \u0219i men\u021binut pe termen lung. Totodat\u0103, av\u00e2nd un profil de siguran\u021b\u0103 bine definit, Taltz a atins \u00een studiile clinice niveluri superioare de r\u0103spuns inclusiv la nivel palmo-plantar, unghial, genital \u0219i la nivelulul scalpului, fiind eficient nu numai la nivel cutanat ci \u0219i la nivel articular.<\/p>\n
TALTZ IN PSORIASIS: SUPERIOR EFFICACY FROM HEAD TO TOE<\/span>
Speakers: Daciana Br\u0103ni\u0219teanu1, Cristina Tutunaru2, Andreea Molodoi3, Elena Porumb-Andrese1<\/span><\/p>\n1MF Grigore T. Popa, Ia\u0219i, 2UMF Craiova, 3Spitalul Municipal Roman<\/p>\n
Keywords: emollients, newborns, infants, side effects, benefits<\/p>\n
Keywords: psoriasis, Taltz, Ixekizumab, IL-17, completely clear skin.
During its almost 30 years of activity in Romania, Lilly has made over 30 innovative medicines available to physicians and patients from therapeutic areas such as diabetes, oncology, dermatology, endocrinology, rheumatology, neurology, urology. Every year, over 100,000 Romanian patients benefit from Lilly’s modern therapies.
Our mission in immunology is to improve the lives of patients and we believe that our drugs can redefine the therapeutic options in psoriasis, atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, axial spondylarthritis, inflammatory bowel disease, which means continuously raising the bar.
Given the chronic inflammatory nature of psoriasis and the multiple associated comorbidities, long-term management of this condition, most often throughout life, is required.
Taltz, a monoclonal antibody with high affinity and specificity for IL-17A, demonstrated efficacy and safety at 5 years, proving that it is a complete treatment for psoriasis patients who want a fast and long-term response. At the same time, with a well-defined safety profile, Taltz has achieved higher levels of response in clinical trials, including at the palm-plantar, nail, genital, and scalp levels, being effective not only on the skin but also on the joints.<\/p>\n
Scurt CV<\/span><\/p>\n\u2013 Profesor universitar, titular de curs de dermatologie, Facultatea de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i
\u2013 Doctor \u00een \u0219tiin\u021be medicale, teza de doctorat \u00een ACNEEA VULGARA (2004)
\u2013 Manager al Centrului de Dermatologie, Venerologie \u0219i Dermatocosmetologie \u201cDermaLux\u201d, din 2004 p\u00e2n\u0103 \u00een prezent
\u2013 \u0218ef sec\u021bie la Clinica Dermatologic\u0103 a Spitalului Clinic C\u0103i Ferate Ia\u0219i
\u2013 Competen\u021be \u00een anatomie patologic\u0103 cutanat\u0103 (Lyon, Fran\u021ba) \u0219i \u00een dermatocosmetologie
\u2013 Cursuri de supraspecializare \u00een Fran\u021ba, Lyon, Universite Lyon 2 (AFSA), cursuri europene de dermatoscopie, boala venoas\u0103 cronic\u0103, psoriazis, anti-aging, injectare de filere, laserterapie etc.
\u2013 Preocup\u0103ri deosebite pentru psoriazis: coordonator al Proiectului Na\u021bional Educa\u021bional \u201cPatologia psoriazisului\u201d, particip\u0103ri \u00een calitate de expert la \u00eent\u00e2lniri interna\u021bionale pe teme de psoriasis (Viena, Atena, Geneva etc.), articole publicate \u00een reviste na\u021bionale \u0219i interna\u021bionale, comunic\u0103ri orale, conferin\u021be, grupuri de lucru \u0219i workshop-uri pe tema psoriazisului
\u2013 Pre\u0219edinte al Asocia\u021biei Dermatologilor din Moldova, Pre\u0219edinte al manifest\u0103rii na\u021bionale cu participare interna\u021bional\u0103 \u201cPrim\u0103vara Dermatologic\u0103 Ie\u0219ean\u0103\u201d;
\u2013 Membru \u00een Comitetul Director al Societ\u0103\u021bii Rom\u00e2ne de Dermatologie
\u2013 Membru \u00een Grupul Interna\u021bional \u201cMedical Reporter\u2019s Academy\u201d, pe probleme de flebologie
\u2013 Membru al: Academiei Europene de Dermatologie, Academiei Americane de Dermatologie, Societ\u0103\u021bii Franceze de Dermatologie, Societ\u0103\u021bii Franceze de Flebologie, Societ\u0103\u021bii Interna\u021bionale de Dermatologie, Societ\u0103\u021bii de Dermatologie Investigativ\u0103, Societ\u0103\u021bii Rom\u00e2ne de Dermatopediatrie, Societ\u0103\u021bii Rom\u00e2ne de Dermatoimunologie, Societ\u0103\u021bii de Medici \u0219i Naturali\u0219ti
\u2013 Coordonator a peste 100 de cursuri de educa\u021bie medical\u0103 continu\u0103 \u0219i de cursuri postuniversitare
\u2013 Peste 400 de conferin\u021be, prelegeri \u0219i comunic\u0103ri orale sus\u021binute la manifest\u0103ri \u0219tiin\u021bifice, mese rotunde, conferin\u021be \u0219i congrese din \u021bar\u0103, nu doar de dermatologie
\u2013 Lector invitat la Congrese Interna\u021bionale ale: Societ\u0103\u021bii Europene de Dermatologie \u0219i Venerologie (EADV), Societ\u0103\u021bii Franceze de Flebologie (SFP), Uniunii Interna\u021bionale de Flebologie (UIP)
\u2013 Expert \u00een Boala Venoas\u0103 Cronic\u0103, \u00een Maladii Transmisibile Sexual, expert dermatolog \u00een solu\u021bionarea unor cazuri medico-legale
\u2013 Decan de Serie desemnat de c\u0103tre studen\u021bi, ca semn de respect \u0219i de recunoa\u0219tere a calit\u0103\u021bii de dasc\u0103l
\u2013 Implicare activ\u0103 \u00een activitatea de cercetare \u0219tiin\u021bific\u0103 (granturi de cercetare \u0219tiin\u021bific\u0103, proiecte na\u021bionale \u0219i interna\u021bionale, studii clinice, consultant \u0219tiin\u021bific, membru \u00een numeroase advisory board-uri etc.)
\u2013 Peste 230 de lucr\u0103ri publicate \u00een \u021bar\u0103 \u0219i \u00een str\u0103in\u0103tate, autoare a 23 c\u0103r\u021bi \u0219i capitole de c\u0103r\u021bi de dermatologie
\u2013 Absolvent\u0103 a Facult\u0103\u021bii de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i, promo\u021bia 1991<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2022\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”4.16″ custom_padding=”61px|0px|69px|0px|false|false” global_colors_info=”{}”][et_pb_column type=”3_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2022<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.16″ _unique_id=”794aaef5-e005-432a-99fb-9ca53e06d67b” title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A” global_colors_info=”{}”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” global_colors_info=”{}”]<\/p>\n
Operatorul PDI 2022<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.16″ text_font=”||||||||” global_colors_info=”{}”]<\/p>\n
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: contact@pdi.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”on|on|on” _builder_version=”4.16″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” disabled=”on” locked=”off” global_colors_info=”{}”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”9252,9464,10556″ fullwidth=”on” disabled_on=”off|off|off” _builder_version=”4.17.1″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off” global_colors_info=”{}”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Prof. Dr. Daciana Elena Br\u0103ni\u0219teanuUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219iSpitalul Clinic Universitar CF Ia\u0219iSimpozion NOVARTIS Cosentyx – It\u2019s all about the patient\u00a0\u2018\u2019Xolair- Game Changer \u00een Urticaria Cronic\u0103 Spontan\u0103\u2019\u2019Prof. Daciana Br\u0103nisteanu – Clinica de Dermatologie, Spitalul Clinic CF Ia\u0219iProf. C\u0103lin Giurcaneanu – Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti;Dr. Alin Nicolescu – Centrul Med. […]<\/p>\n","protected":false},"author":2,"featured_media":11595,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[12],"tags":[],"class_list":["post-11586","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lectori"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts\/11586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/comments?post=11586"}],"version-history":[{"count":11,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts\/11586\/revisions"}],"predecessor-version":[{"id":11638,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts\/11586\/revisions\/11638"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/media\/11595"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/media?parent=11586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/categories?post=11586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/tags?post=11586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Cosentyx – It\u2019s all about the patient<\/span> Cuvinte cheie: omalizumab, urticarie cronic\u0103 spontan\u0103, papule, angioedem.<\/p>\n <\/p>\n Urticaria Cronic\u0103 Spontan\u0103 este o afec\u021biune cronic\u0103 intermitent\u0103, caracterizat\u0103 prin apari\u021bia spontan\u0103 a papulelor sau\/\u0219i a angioedemului, in fiecare zi sau aproape in toate zilele, pentru cel pu\u021bin 6 s\u0103pt\u0103m\u00e2ni, f\u0103r\u0103 un stimul extern evident. Scopul tratamentului \u00een urticaria cronic\u0103 spontan\u0103 este obtinerea controlului complet al bolii cu absen\u0163a semnelor \u015fi simptomelor, precum \u015fi \u00eembunat\u0103\u021birea calit\u0103\u0163ii vie\u0163ii. Acest lucru poate fi m\u0103surat prin utilizarea \u00een practica clinic\u0103 a chestionarelor: UAS7- scorul de activitate al urticariei \u015fi DLQI- indicele dermatologic de calitate a vie\u0163ii, care ajuta in evaluarea rapid\u0103 a severit\u0103\u021bii UCS \u0219i in stabilirea algoritmului potrivit de tratament.<\/p>\n Omalizumab este indicat ca tratament adjuvant al UCS la pacien\u0163i adul\u0163i \u015fi adolescen\u0163i (12 ani \u0219i peste) cu r\u0103spuns neadecvat la tratamentul cu antihistaminice H1. \u00cen studiile de faz\u0103 III (Asteria I, Asteria II, Glacial) omalizumab administrat in doz\u0103 de 300 mg a demonstrat \u00een mod constant \u00eembunata\u021biri semnificative ale simptomelor UCS \u00een compara\u021bie cu placebo. <\/span><\/p>\n Simpozion NOVARTIS<\/span><\/p>\n Cosentyx – It\u2019s all about the patient<\/span> Boala psoriazic\u0103 este o afec\u021biune sistemic\u0103 inflamatorie, mediat\u0103 imun, progresiv\u0103, care afecteaz\u0103 \u00eentreg organismul, trec\u00e2nd dincolo de piele. Pentru pacien\u021bii cu boal\u0103 psoriazic\u0103, pielea este doar unul dintre aspectele bolii.<\/p>\n Pacien\u021bii \u00ee\u0219i doresc un tratament cu eficien\u021b\u0103 dovedit\u0103 \u0219i profil favorabil de siguran\u021b\u0103, care s\u0103 \u021binteasc\u0103 toate manifest\u0103rile bolii psoriazice: Date din literatura de specialitate relev\u0103 c\u0103, \u00een medie, exist\u0103 o \u00eent\u00e2rziere a diagnosticului de psoriazis de aproximativ 2,6 ani de la debutul bolii, \u00een timp ce pentru diagnosticul de artrit\u0103 psoriazic\u0103 aceast\u0103 \u00eent\u00e2rziere este \u00een medie de 1,8 ani de la debutul simptomelor.<\/p>\n Cu at\u00e2t mai important\u0103 devine cunoa\u0219terea de c\u0103tre pacient a semnelor \u0219i simptomelor bolii psoriazice \u00eenc\u0103 din stadiul ini\u021bial.<\/p>\n Un studiu recent derulat a scos \u00een eviden\u021b\u0103 faptul c\u0103 numero\u0219i pacien\u021bi cu boal\u0103 psoriazic\u0103 nu realizeaz\u0103 complexitatea acestei afec\u021biuni \u0219i nici rela\u021bia \u00eentre diferitele manifest\u0103ri ale bolii \u0219i comorbidit\u0103\u021bile asociate.<\/p>\n Din acela\u0219i studiu reiese c\u0103, \u00een ceea ce prive\u0219te calitatea vie\u021bii, 73% dintre pacien\u021bi raporteaz\u0103 un impact moderat p\u00e2n\u0103 la foarte mare sau extrem de mare al bolii psoriazice.<\/p>\n Tratamentul eficient \u0219i complet al manifest\u0103rilor multiple ale bolii psoriazice este esen\u021bial pentru \u00eembun\u0103t\u0103\u021birea calit\u0103\u021bii vie\u021bii pacien\u021bilor.<\/p>\n Utilizat la nivel mondial la peste 500.000 pacien\u021bi, \u00een indica\u021biile aprobate, \u0219i f\u0103r\u0103 eviden\u021bierea de noi semnale privind siguran\u021ba de-a lungul a 5 ani, Cosentyx asigur\u0103 tratamentul complet pentru boala psoriazic\u0103.<\/p>\n \u00cencep\u00e2nd din timp tratamentul bolii psoriazice \u0219i \u021bintind direct cauza bolii, inflama\u021bia sistemic\u0103, cu Cosentyx, ob\u021binem \u00een timp scurt o eficacitate \u00eenalt\u0103 care este sus\u021binut\u0103 pe termen lung, nu doar la nivelul pieli, dar \u0219i la nivel articular, \u00een condi\u021biile unui profil de siguran\u021b\u0103 favorabil \u0219i men\u021binut \u00een timp.<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Simpozion NDMEDHEALTH \/ URIAGE<\/span><\/p>\n INOVA\u021aIA URIAGE BARI\u00c9SUN 100: ULTRA PROTEC\u021aIE PENTRU PREVENIREA DETERIOR\u0102RII CELULARE \u0218I FOTO\u00ceMB\u0102TR\u00c2NIRII INDUSE DE RAZELE UV \u0218I LUMINA ALBASTR\u0102<\/span> Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i. Spitalul Clinic Universitar CF Ia\u0219i<\/p>\n Cuvinte cheie: fotoprotec\u021bie, lumina albastr\u0103, piele intolerant\u0103, protec\u021bie a ADN-ului celular<\/p>\n Tenul deschis si foarte deschis, pacien\u021bii cu piele intolerant\u0103, keratoze \u0219i fotodermatoze actinice sau cu diverse patologii care pot fi agravate de soare precum cuperoza, vitiligo, herpes, melasma au nevoie de produse speciale de protec\u021bie solar\u0103. URIAGE BARI\u00c9SUN 100 INNOVATION: ULTRA PROTECTION TO PREVENT CELL DAMAGE AND PHOTO-AGING FROM UV AND BLUE LIGHT<\/span> \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, Ia\u0219i. CF Ia\u0219i University Clinical Hospital<\/p>\n Keywords: photo protection, blue light, intolerant skin, cellular DNA protection<\/p>\n Fair and very fair skin, patients with actinic keratoses and photo-dermatoses or with pathologies and intolerant skin that can be aggravated by the sun such as couperose, vitiligo, herpes, melasma need special sun protection products. Simpozion NDMEDHEALTH \/ ISDIN<\/span><\/p>\n ALGORITMUL TERAPEUTIC \u00ceN KERATOZA ACTINIC\u0102 \u0218I ROLUL FOTOPROTEC\u021aIEI ISDIN \u00ceN PREVEN\u021aIA CANCERULUI DE PIELE NON-MELANOM<\/span> Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i. Spitalul Clinic Universitar CF Ia\u0219i<\/p>\n Cuvinte cheie: keratoz\u0103 actinic\u0103, cancer de piele non-melanon, fotoliaz\u0103 \u00eencapsulat\u0103 \u00een lipozomi<\/p>\n Keratoza actinic\u0103 (KA) este o form\u0103 frecvent \u00eent\u00e2lnit\u0103 de leziune pre-canceroas\u0103 a pielii, cauzat\u0103 de expunerea cronic\u0103 la radia\u021biile UV, a c\u0103ror principal\u0103 surs\u0103 este soarele. THERAPEUTIC ALGORITHM IN ACTINIC KERATOSIS AND THE ROLE OF ISDIN PHOTOPROTECTION IN THE PREVENTION OF NON MELANOMA SKIN CANCER<\/span> Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i. Spitalul Clinic Universitar CF Ia\u0219i<\/p>\n Key words: actinic keratosis, non melanona skin cancer, photolyase encapsulated in liposomes<\/p>\n Actinic Keratosis (AK) is a frequent form of pre-cancerous skin lesion, caused by cronic exposure to UV radiation, with the sun as the main source. Simpozion Lilly<\/span><\/p>\n TALTZ \u00ceN PSORIAZIS: EFICACITATE SUPERIOAR\u0102 DIN CAP P\u00c2N\u0102-N PICIOARE<\/span> 1Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, 2Universitatea de Medicin\u0103 \u0219i Farmacie Craiova, 3Spitalul Municipal Roman<\/p>\n Cuvinte cheie: Psoriazis, Taltz, Ixekizumab, IL-17, piele complet curat\u0103. TALTZ IN PSORIASIS: SUPERIOR EFFICACY FROM HEAD TO TOE<\/span> 1MF Grigore T. Popa, Ia\u0219i, 2UMF Craiova, 3Spitalul Municipal Roman<\/p>\n Keywords: emollients, newborns, infants, side effects, benefits<\/p>\n Keywords: psoriasis, Taltz, Ixekizumab, IL-17, completely clear skin. Scurt CV<\/span><\/p>\n \u2013 Profesor universitar, titular de curs de dermatologie, Facultatea de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2022\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”4.16″ custom_padding=”61px|0px|69px|0px|false|false” global_colors_info=”{}”][et_pb_column type=”3_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n Contacteaz\u0103 operatorul PDI 2022<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.16″ _unique_id=”794aaef5-e005-432a-99fb-9ca53e06d67b” title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A” global_colors_info=”{}”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” global_colors_info=”{}”]<\/p>\n Operatorul PDI 2022<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.16″ text_font=”||||||||” global_colors_info=”{}”]<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Adresa: Str. A. Panu nr. 13, Iasi<\/span> [\/et_pb_text][et_pb_text disabled_on=”on|on|on” _builder_version=”4.16″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” disabled=”on” locked=”off” global_colors_info=”{}”]<\/p>\n Parteneri Media<\/p>\n [\/et_pb_text][et_pb_gallery gallery_ids=”9252,9464,10556″ fullwidth=”on” disabled_on=”off|off|off” _builder_version=”4.17.1″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off” global_colors_info=”{}”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Prof. Dr. Daciana Elena Br\u0103ni\u0219teanuUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219iSpitalul Clinic Universitar CF Ia\u0219iSimpozion NOVARTIS Cosentyx – It\u2019s all about the patient\u00a0\u2018\u2019Xolair- Game Changer \u00een Urticaria Cronic\u0103 Spontan\u0103\u2019\u2019Prof. Daciana Br\u0103nisteanu – Clinica de Dermatologie, Spitalul Clinic CF Ia\u0219iProf. C\u0103lin Giurcaneanu – Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti;Dr. Alin Nicolescu – Centrul Med. […]<\/p>\n","protected":false},"author":2,"featured_media":11595,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[12],"tags":[],"class_list":["post-11586","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lectori"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts\/11586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/comments?post=11586"}],"version-history":[{"count":11,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts\/11586\/revisions"}],"predecessor-version":[{"id":11638,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/posts\/11586\/revisions\/11638"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/media\/11595"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/media?parent=11586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/categories?post=11586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pdi.ro\/2022\/wp-json\/wp\/v2\/tags?post=11586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\u00a0\u2018\u2019Xolair- Game Changer \u00een Urticaria Cronic\u0103 Spontan\u0103\u2019\u2019
Prof. Daciana Br\u0103nisteanu – Clinica de Dermatologie, Spitalul Clinic CF Ia\u0219i
Prof. C\u0103lin Giurcaneanu – Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti;
Dr. Alin Nicolescu – Centrul Med. de Diagnostic si Tratament \u201cS.R.I.\u201d, Bucure\u0219ti<\/span><\/p>\n
Urticaria cronica spontana are un impact major asupra calitatii vietii si activitatilor zilnice ale pacientilor afectand multiple aspecte precum pierderea productivitatii, absenta de la locul de munca sau afectarea emotionala si psihologica.
Papulele \u0219i angioedemul sunt raportate in procente de 33 p\u00e2na la 67% la pacien\u021bii cu UCS, angioedemul singur fiind prezent doar la 1\u221213% din pacien\u021bi.
Terapia simptomatic\u0103 cu antihistaminice H1 este singura terapie de prim\u0103 inten\u021bie in UCS, dar \u00eensa efectul terapeutic este dovedit la mai pu\u021bin de 50 % dintre pacien\u021bii cu urticarie cronic\u0103 spontan\u0103, simptomele \u0219i RA ale tratamentului determin\u00e2nd pierderea energiei \u0219i afectarea somnului.<\/p>\n
Doza recomandat\u0103 este de 300 mg, subcutanat, la intervale de 4 s\u0103pt\u0103m\u00e2ni.<\/p>\n
Terapia biologic\u0103, omalizumab a demonstrat c\u0103 ob\u021bine controlul rapid \u0219i complet al urticariei cronice spontane, av\u00e2nd un profil de siguran\u021b\u0103 dovedit atat de studiile clinice de faza III c\u00e2t si de eviden\u021bele real world.<\/p>\n
\u00a0Moderator
Prof Univ Dr Daciana Elena Br\u0103ni\u0219teanu
Lectori
Prof Univ Dr Codrina Ancu\u021ba
Dr Georgiana Mih\u0103il\u0103<\/span><\/p>\n
-Vindecarea leziunilor cutanate
-Remisiunea sus\u021binut\u0103 a artritei psoriazice
-Tratamentul complet al tuturor manifestarilor bolii, inclusiv al formelor \u201edificil de tratat\u201d
-Controlul comorbidit\u0103\u021bilor prezente \u0219i prevenirea aparitiei altor comorbidit\u0103\u021bi
-\u00cembun\u0103t\u0103\u021birea calit\u0103\u021bii vie\u021bii , at\u00e2t fizic c\u00e2t \u0219i psihic
\u00cendeplinirea acestor deziderate presupune diagnosticul, \u0219i implicit, tratamentul precoce al bolii.<\/p>\n
\u00a0Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Aici intervine conceptul BARI\u00c9SUN 100, un produs ULTRA FOTOPROTECTOR ideal pentru to\u021bi pacien\u021bii cu fototipuri deschise \u0219i foarte deschise, cu intoleran\u021b\u0103 la soare \u0219i fotodermatoze, dermatoze agravate sau risc de sensibilizare la soare prin diferite tratamente.
Bari\u00e9sun 100 garanteaz\u0103 ultra-protec\u021bie pe trei direc\u021bii. \u00cen primul r\u00e2nd, datorit\u0103 ac\u021biunii brevetului Bari\u00e9sun, care limiteaz\u0103 pierderea de ap\u0103 transepidermic\u0103. Complexul de filtre organice UV ofer\u0103 protec\u021bie anti-UVA \u0219i anti-UVB (raze scurte \u0219i lungi) \u00een timp ce complexul patentat PVP + polyquaternium limiteaz\u0103 penetrarea \u00een epiderm\u0103 a filtrelor optimiz\u00e2nd astfel fotoprotec\u021bia.
Aceast\u0103 tripl\u0103 protec\u021bie include \u0219i propriet\u0103\u021bile antioxidante \u0219i de protec\u021bie a ADN-ului a apei termale Uriage combinate cu vitaminele C \u0219i E, care limiteaz\u0103 formarea de radicali liberi genera\u021bi de expunerea la soare.
\u00cen cele din urm\u0103, inova\u021bia major\u0103 a acestei game, brevetul Telomeres Protect previne deteriorarea celular\u0103 \u0219i foto\u00eemb\u0103tr\u00e2nirea datorit\u0103 unui extract patentat de arthrospira platensis (spirulin\u0103) care limiteaz\u0103 formarea telomerilor scur\u021bi prin calea mTOR, iar aquasponginele ofer\u0103 protec\u021bie anti-deshidratare.
Brevetul Telomeres Protect va reduce daunele celulare \u0219i va preveni foto\u00eemb\u0103tr\u00e2nirea prin trei ac\u021biuni. O reducere a activ\u0103rii complexului mTOR1, implicat \u00een mecanismele carcinogenezei, o reducere a produc\u021biei de progerin\u0103, o protein\u0103 toxic\u0103 produs\u0103 \u00een timpul \u00eemb\u0103tr\u00e2nirii \u0219i, \u00een final, o reducere a procentului de telomeri scur\u021bi.<\/p>\n
\u00a0Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Hence the launch of BARIESUN 100, an ULTRA PHOTOPROTECTIVE product ideal for all your patients with light and very light phototypes, intolerant to the sun and all cases of photodermatoses, aggravated dermatoses or risk of sensitization to the sun by the various treatments.
Bari\u00e9sun 100 guarantees ultra-protection, triple protection. First of all, thanks to the action of the Bari\u00e9sun patent, which limits the transepidermal water loss. The complex of organic UV filters provides long and short anti-UVA and anti-UVB protection while the patented PVP + polyquaternium association limits the epidermal penetration of the filters thus optimizing photoprotection.
This triple protection also includes the antioxidant and DNA-protecting properties of Uriage Thermal Water combined with vitamins C and E, which limit the formation of free radicals generated by sun exposure.
Finally, the major innovation of this range, the Telomeres Protect patent, which prevents cellular damages and photoaging thanks to a patented extract of arthrospira platensis (spirulina) that limits the formation of short telomeres via the mTOR pathway. Not to mention the aquaspongins providing anti-dehydration protection.
The Telomeres Protect patent will reduce cellular damage and prevent photoaging through three actions. A reduction in the activation of the mTOR1 complex, involved in the mechanisms of carcinogenesis, a reduction in the production of progerin, a toxic protein produced during aging and finally a reduction in the percentage of short telomeres.<\/p>\n
\u00a0Daciana Br\u0103ni\u0219teanu<\/span><\/p>\n
Abordarea terapeutic\u0103 a KA depinde de \u00eencadrarea pacientului \u00een func\u021bie de recomand\u0103rile stabilite de Liga Interna\u021bional\u0103 a Societ\u0103\u021bilor Dermatologice (ILDS) \u0219i trebuie s\u0103 \u021bin\u0103 cont de: num\u0103rul, modul de distribuire \u0219i caracteristicile leziunilor, de preferin\u021ba pacientului privind modul de tratament (acas\u0103 sau la cabinet), durata terapiei, toleran\u021ba la efectele secundare (de exemplu, durere, inflama\u021bie, hipo-pigmentare, cicatrici), disponibilitate \u0219i cost.
Terapia fotodinamic\u0103 (TFD) \u0219i Crioterapia reprezint\u0103 abord\u0103ri terapeutice consacrate \u00een tratamentul KA.
Totu\u0219i, dup\u0103 acestea, strategiile de protec\u021bie solar\u0103 sunt importante pentru a reduce riscul form\u0103rii de noi leziuni \u0219i\/sau nevoia de a folosi din nou TFD \u0219i Crioterapie.
Studii recente, majoritatea efectuate \u00een Europa, dovedesc valoarea clinic\u0103 a produselor de protec\u021bie solar\u0103 care con\u021bin enzime de fotoliaz\u0103 \u00eencapsulate \u00een lipozomi \u00een cazul pacien\u021bilor care urmeaz\u0103 un tratament pentru KA, al pacien\u021bilor cu grad de risc Fitzpatrick foarte ridicat (I-III) \u0219i al celor care necesit\u0103 suport suplimentar \u00een chemo-preven\u021bie \u00een cazul bolilor cronice sau tratamentelor medicale.
Fotoliaza repar\u0103 muta\u021biile \u0219i leziunile de ADN induse de radia\u021biile UV, influen\u021b\u00e2nd astfel etapele ini\u021biale de carcinogenez\u0103.
Strategia de fotoprotec\u021bie+fotoreparare trebuie inclus\u0103 \u00een algoritmul terapeutic de preven\u021bie \u0219i tratament \u00een KA \u0219i cancer de piele non-melanom. Folosirea ISDIN Eryfotona, cu tehnologie inovatoare DNA Repairsomes \u0219i fotoliaz\u0103 \u00eencapsulat\u0103 \u00een lipozomi a demonstrat rezultate ca monoterapie pentru pacien\u021bii cu form\u0103 u\u0219oar\u0103 de KA, precum \u0219i ca adjuvant \u00een TFD \u0219i crioterapie.<\/p>\n
\u00a0Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
The therapeutic approach in AK depends on the patients\u2019 classification based on the recommendations of the International Leage of Dermatological Societies (ILDS) and must consider: the number, distribution and characteristics of the lesions, patient\u2019s preffered way of treatment (at home or in doctor\u2019s office), duration of the therapy, tolerance to side effects (e.g. pain, inflamation, hypo-pigmentation, scarring), availability and cost.
Photodynamic Therapy (PDT) and Cryotherapy represent standard therapeutic approaches in the treatment of AK.
However, after them, sun protection strategies are important for reducing the risc of new lesions and\/or the need to use PDT and Cryotherapy again.
Recent studies, most of them performed in Europe, confirm the clinical value of photoprotection products containing photolyase enzimes encapsulated in liposomes in pacients that follow a treatment for KA, those with very high Fitzpatrick risk (I-III) and those who need additional care in chemo-prevention in cronical illnesses or medical treatments.
The photolyase repairs the DNA mutations and lesions caused by the UV radiation, thus influencing the initial stages of carcinogenesis.
A photoprotection and photorepair strategy must be included in the therapeutic algorithm of prevention and treatment of AK and NMSC. ISDIN Eryfotona, with innovative technology of DNA Repairsomes and photolyase encapsulated in lipozomes, has proven results when used as monotherapy in patients with less severe forms of AK, as well as co-adjuvant in PDT and Cryotherapy.<\/p>\n
Lectori: Daciana Br\u0103ni\u0219teanu1, Cristina Tutunaru2, Andreea Molodoi3, Elena Porumb-Andrese1<\/span><\/p>\n
De-a lungul celor aproape 30 de ani de activitate \u00een Rom\u00e2nia, Lilly a pus la dispozi\u021bia medicilor \u0219i pacien\u021bilor peste 30 de medicamente inovatoare \u00een domenii precum diabetul zaharat, oncologia, dermatologia, endocrinologia, reumatologia, neurologia, urologia. Anual, peste 100.000 de pacien\u021bi rom\u00e2ni beneficiaz\u0103 de terapiile moderne ale companiei Lilly.
Misiunea noastr\u0103 \u00een imunologie este aceea de a \u00eembun\u0103t\u0103\u021bi via\u021ba pacien\u021bilor \u0219i consider\u0103m c\u0103 medicamentele noastre pot redefini op\u021biunile terapeutice \u00een psoriazis, dermatita atopic\u0103, artrita psoriazic\u0103, artrita reumatoid\u0103, spondiloartritele axiale, bolile inflamatorii intestinale, acest lucru \u00eensemn\u00e2nd ridicarea continu\u0103 a \u0219tachetei \u00een acest domeniu.
\u021ain\u00e2nd cont de natura inflamatorie cronic\u0103 a psoriazisului \u0219i de multiplele comorbidit\u0103\u021bi asociate, este nevoie de o gestionare pe termen lung a acestei afec\u021biuni, de cele mai multe ori pe toat\u0103 durata vie\u021bii.
Taltz, anticorp monoclonal cu afinitate ridicat\u0103 \u0219i specificitate pentru interleukina 17A, \u0219i-a demonstrat eficacitatea \u0219i siguran\u021ba la 5 ani de tratament, dovedind c\u0103 este un tratament complet pentru pacien\u021bii cu psoriazis care \u00ee\u0219i doresc un r\u0103spuns rapid \u0219i men\u021binut pe termen lung. Totodat\u0103, av\u00e2nd un profil de siguran\u021b\u0103 bine definit, Taltz a atins \u00een studiile clinice niveluri superioare de r\u0103spuns inclusiv la nivel palmo-plantar, unghial, genital \u0219i la nivelulul scalpului, fiind eficient nu numai la nivel cutanat ci \u0219i la nivel articular.<\/p>\n
Speakers: Daciana Br\u0103ni\u0219teanu1, Cristina Tutunaru2, Andreea Molodoi3, Elena Porumb-Andrese1<\/span><\/p>\n
During its almost 30 years of activity in Romania, Lilly has made over 30 innovative medicines available to physicians and patients from therapeutic areas such as diabetes, oncology, dermatology, endocrinology, rheumatology, neurology, urology. Every year, over 100,000 Romanian patients benefit from Lilly’s modern therapies.
Our mission in immunology is to improve the lives of patients and we believe that our drugs can redefine the therapeutic options in psoriasis, atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, axial spondylarthritis, inflammatory bowel disease, which means continuously raising the bar.
Given the chronic inflammatory nature of psoriasis and the multiple associated comorbidities, long-term management of this condition, most often throughout life, is required.
Taltz, a monoclonal antibody with high affinity and specificity for IL-17A, demonstrated efficacy and safety at 5 years, proving that it is a complete treatment for psoriasis patients who want a fast and long-term response. At the same time, with a well-defined safety profile, Taltz has achieved higher levels of response in clinical trials, including at the palm-plantar, nail, genital, and scalp levels, being effective not only on the skin but also on the joints.<\/p>\n
\u2013 Doctor \u00een \u0219tiin\u021be medicale, teza de doctorat \u00een ACNEEA VULGARA (2004)
\u2013 Manager al Centrului de Dermatologie, Venerologie \u0219i Dermatocosmetologie \u201cDermaLux\u201d, din 2004 p\u00e2n\u0103 \u00een prezent
\u2013 \u0218ef sec\u021bie la Clinica Dermatologic\u0103 a Spitalului Clinic C\u0103i Ferate Ia\u0219i
\u2013 Competen\u021be \u00een anatomie patologic\u0103 cutanat\u0103 (Lyon, Fran\u021ba) \u0219i \u00een dermatocosmetologie
\u2013 Cursuri de supraspecializare \u00een Fran\u021ba, Lyon, Universite Lyon 2 (AFSA), cursuri europene de dermatoscopie, boala venoas\u0103 cronic\u0103, psoriazis, anti-aging, injectare de filere, laserterapie etc.
\u2013 Preocup\u0103ri deosebite pentru psoriazis: coordonator al Proiectului Na\u021bional Educa\u021bional \u201cPatologia psoriazisului\u201d, particip\u0103ri \u00een calitate de expert la \u00eent\u00e2lniri interna\u021bionale pe teme de psoriasis (Viena, Atena, Geneva etc.), articole publicate \u00een reviste na\u021bionale \u0219i interna\u021bionale, comunic\u0103ri orale, conferin\u021be, grupuri de lucru \u0219i workshop-uri pe tema psoriazisului
\u2013 Pre\u0219edinte al Asocia\u021biei Dermatologilor din Moldova, Pre\u0219edinte al manifest\u0103rii na\u021bionale cu participare interna\u021bional\u0103 \u201cPrim\u0103vara Dermatologic\u0103 Ie\u0219ean\u0103\u201d;
\u2013 Membru \u00een Comitetul Director al Societ\u0103\u021bii Rom\u00e2ne de Dermatologie
\u2013 Membru \u00een Grupul Interna\u021bional \u201cMedical Reporter\u2019s Academy\u201d, pe probleme de flebologie
\u2013 Membru al: Academiei Europene de Dermatologie, Academiei Americane de Dermatologie, Societ\u0103\u021bii Franceze de Dermatologie, Societ\u0103\u021bii Franceze de Flebologie, Societ\u0103\u021bii Interna\u021bionale de Dermatologie, Societ\u0103\u021bii de Dermatologie Investigativ\u0103, Societ\u0103\u021bii Rom\u00e2ne de Dermatopediatrie, Societ\u0103\u021bii Rom\u00e2ne de Dermatoimunologie, Societ\u0103\u021bii de Medici \u0219i Naturali\u0219ti
\u2013 Coordonator a peste 100 de cursuri de educa\u021bie medical\u0103 continu\u0103 \u0219i de cursuri postuniversitare
\u2013 Peste 400 de conferin\u021be, prelegeri \u0219i comunic\u0103ri orale sus\u021binute la manifest\u0103ri \u0219tiin\u021bifice, mese rotunde, conferin\u021be \u0219i congrese din \u021bar\u0103, nu doar de dermatologie
\u2013 Lector invitat la Congrese Interna\u021bionale ale: Societ\u0103\u021bii Europene de Dermatologie \u0219i Venerologie (EADV), Societ\u0103\u021bii Franceze de Flebologie (SFP), Uniunii Interna\u021bionale de Flebologie (UIP)
\u2013 Expert \u00een Boala Venoas\u0103 Cronic\u0103, \u00een Maladii Transmisibile Sexual, expert dermatolog \u00een solu\u021bionarea unor cazuri medico-legale
\u2013 Decan de Serie desemnat de c\u0103tre studen\u021bi, ca semn de respect \u0219i de recunoa\u0219tere a calit\u0103\u021bii de dasc\u0103l
\u2013 Implicare activ\u0103 \u00een activitatea de cercetare \u0219tiin\u021bific\u0103 (granturi de cercetare \u0219tiin\u021bific\u0103, proiecte na\u021bionale \u0219i interna\u021bionale, studii clinice, consultant \u0219tiin\u021bific, membru \u00een numeroase advisory board-uri etc.)
\u2013 Peste 230 de lucr\u0103ri publicate \u00een \u021bar\u0103 \u0219i \u00een str\u0103in\u0103tate, autoare a 23 c\u0103r\u021bi \u0219i capitole de c\u0103r\u021bi de dermatologie
\u2013 Absolvent\u0103 a Facult\u0103\u021bii de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i, promo\u021bia 1991<\/p>\n<\/span><\/p>\n
Tel.: 0332.40.88.00-05<\/span>
E-mail: contact@pdi.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n